Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Global Non-Cystic Fibrosis Bronchiectasis Market $1.6 Billion by 2031

The global market for non-cystic fibrosis bronchiectasis estimated to reach $1.6 billion by 2031, growing at a CAGR of 7.1% over the forecast period, driven by increasing prevalence of bronchiectasis and other respiratory diseases, early diagnosis of primary lung diseases, growing demand for antibiotics, as well as airway clearance systems.

Global Non-Cystic Fibrosis Bronchiectasis Market

Non-Cystic Fibrosis Bronchiectasis (NCFBE) is a heterogeneous and increasingly prevalent chronic pulmonary disease that is associated with significant morbidity. It is characterized by abnormal bronchial dilatation, that often leads to recurrent airway infection and inflammation.

  • Bronchiectasis not due to cystic fibrosis is characterized radiologically by permanent dilation of the bronchi, and clinically by a syndrome of cough, sputum production and recurrent respiratory infections. Bronchiectasis represents the final common pathway of a number of infectious, genetic, autoimmune, developmental and allergic disorders and is highly heterogeneous in its etiology, impact and prognosis.
  • The prevalence of bronchiectasis has been historically underestimated. International data show an increase in the prevalence of bronchiectasis over recent years. United States and Europe reported an increase in hospitalizations for bronchiectasis in in the recent past years, with an average increase in the age-adjusted rate of 2.9% per year. Formerly regarded as a rare disease, bronchiectasis is now increasingly recognized and a renewed interest in the condition is stimulating drug development and clinical research.

There are systematic approaches to treatment, such as sputum clearance techniques, prompt treatment of exacerbations and, in certain circumstances, regular antibiotic therapy. First-line therapy is airway clearance. In patients whose symptoms are not improving, mucolytics or long-term antibiotics should be considered.

  • Pulmonary exacerbations should be treated promptly with appropriate antibiotics by the appropriate route and at the correct dose and course length. Mucolytics can be used as an adjunct to chest clearance. Hypertonic saline is used as a first-line treatment.
  • Most physicians recommend mucus clearance as the mainstay of therapy in bronchiectasis. Consensus guidelines recommend that all patients with bronchiectasis receive some instruction in physiotherapy, even if for very mild patients, they only perform physiotherapy during exacerbations.
    • Effective airway clearance, coupled with maintaining good hydration, is an integral component of managing bronchiectasis, both in the long term and in the context of an acute exacerbation.

The global market for non-cystic fibrosis bronchiectasis research report provides market size ($million 2021 to 2031), market share analysis, growth trends and forecast (CAGR%, 2024 to 2031).

The global market for non-cystic fibrosis bronchiectasis segmented by treatment [pharmacological treatment – antibiotics (oral antibiotics, intravenous antibiotics, inhaled antibiotics), bronchodilators, mucolytic agents, corticosteroids], non-pharmacological treatment [airway clearance therapy (high frequency chest wall oscillation therapy)], disease severity (mild, moderate, severe), end user (hospitals, physician clinics, home care), pipeline analysis, and geography.

  • Based on the broader treatment categories, the pharmacological treatment segment accounted for the largest share of the total bronchiectasis market. Among these, the antibiotics treatment segment dominated the global NCFB market, and also expected to witness the fastest growth rate in the coming years.
    • The three main indications for antibiotic use in patients with bronchiectasis include management of pulmonary exacerbations, maintenance therapy, and eradication of newly acquired pathogens. Antibiotics are the most commonly prescribed treatment to treat bacterial infections that can cause inflammation and damage to the airways in patients with bronchiectasis. Oral antibiotics are the most common type of antibiotic used for bronchiectasis.
    • Bronchodilators are used to open up the airways and make it easier to breathe.
    • Mucolytic agents help to thin mucus so that it can be coughed up more easily.
      • The bronchodilator and mucolytic agents are also commonly used to manage symptoms such as coughing and shortness of breath. Corticosteroids are used to reduce inflammation in the airways.
  • In terms of end users, the hospitals segment accounted for the majority of revenue share of the global NCFBE market, whereas the home care providers segment predicted to register the fastest CAGR during the forecast period.
    • Hospitals provide the most comprehensive care for people with bronchiectasis. They have the resources to diagnose and treat the disease, as well as to provide supportive care, such as oxygen therapy and rehabilitation.
    • Physician clinics can also provide care for people with bronchiectasis. They may not have the same resources as hospitals, but they can still provide diagnosis and treatment, as well as supportive care.
    • Home care providers can provide care for people with bronchiectasis who are unable to leave their homes. They can provide assistance with activities of daily living, such as bathing, dressing, and cooking. They can also provide respiratory therapy and other supportive care.

The global market for non-cystic fibrosis bronchiectasis research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

In addition, the global market for non-cystic fibrosis bronchiectasis report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global market for non-cystic fibrosis bronchiectasis and profiled in this report include Bayer AG, Electromed, Inc., Hill-Rom Holdings, Inc., Insmed, Inc., Merck & Co., Inc. (Sigma–Aldrich), Novartis AG, Pharmaxis Ltd., Philips Respironics, Respiratory Technologies, Inc., Roche Holding AG (F. Hoffmann-La Roche AG / Genentech), Tactile Medical, Inc., and Teva Pharmaceutical Industries Ltd.

  • Treatment
    • Pharmacological Treatment
      • Antibiotics
        • Oral Antibiotics
        • Intravenous Antibiotics
        • Inhaled Antibiotics
      • Bronchodilators
      • Mucolytic Agents
      • Corticosteroids
    • Non-pharmacological Treatment
      • Airway Clearance Therapy (ACT)
        • High Frequency Chest Wall Oscillation (HFCWO) Therapy
  • Disease Severity
    • Mild
    • Moderate
    • Severe
  • End User
    • Hospitals
    • Physician Clinics
    • Home Care
  • Pipeline Analysis
  • Company Profiles
    • Bayer AG
    • Electromed, Inc.
    • Hill-Rom Holdings, Inc.
    • Insmed, Inc.
    • Merck & Co., Inc. (Sigma–Aldrich)
    • Novartis AG
    • Pharmaxis Ltd.
    • Philips Respironics
    • Respiratory Technologies, Inc.
    • Roche Holding AG (F. Hoffmann-La Roche AG / Genentech)
    • Tactile Medical, Inc.
    • Teva Pharmaceutical Industries Ltd.

To request Table of Contents and Sample Pages of this report:
https://www.ihealthcareanalyst.com/report/non-cystic-fibrosis-bronchiectasis-market/

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]

    Subject*

    Message*

    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com